Exelixis (EXEL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
15 Apr, 2026Executive summary
Annual meeting scheduled for May 26, 2026, with virtual participation available for shareholders.
Shareholders are encouraged to review proxy materials and vote by May 25, 2026.
Voting matters and shareholder proposals
Election of eleven director nominees to serve until the next annual meeting.
Ratification of Ernst & Young LLP as independent auditor for the fiscal year ending January 1, 2027.
Amendment and restatement of the 2017 Equity Incentive Plan to increase authorized shares by 2,000,000.
Advisory vote on executive compensation (say-on-pay) for named executive officers.
Provision for other business to be addressed as may properly come before the meeting.
Board of directors and corporate governance
Eleven nominees listed for election, including individuals with diverse backgrounds in science, medicine, and business.
Latest events from Exelixis
- Q1 2026 saw 10% revenue growth, strong cabozantinib sales, and zanzalintinib NDA progress.EXEL
Q1 20266 May 2026 - Zanzalintinib advances as a next-gen TKI amid strong growth and expanding oncology pipeline.EXEL
TD Cowen 46th Annual Health Care Conference29 Apr 2026 - Proposal No. 3 requires a majority vote, with abstentions counting against and broker non-votes ignored.EXEL
Proxy filing17 Apr 2026 - Shareholders to vote on directors, auditor, equity plan, and pay amid strong growth and ESG focus.EXEL
Proxy filing15 Apr 2026 - Zanzalintinib and CABOMETYX anchor growth in GI/GU oncology, with robust pipeline momentum.EXEL
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Zanza and new indications drive growth, targeting $2.4B revenue and leadership in key oncology markets.EXEL
The Citizens Life Sciences Conference 202611 Mar 2026 - Key RCC and CRC trials signal evolving standards and support double-digit growth outlook for 2026.EXEL
Leerink Global Healthcare Conference 202610 Mar 2026 - Strong 2025 growth led by cabozantinib, pipeline progress, and expanded stock repurchases.EXEL
Q4 202511 Feb 2026 - Q2 2024 revenues hit $637M, net income $226M, with CABOMETYX and pipeline progress leading growth.EXEL
Q2 20242 Feb 2026